We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $765K

35% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

13% more capital invested

Capital invested by funds: $841M → $953M (+$111M)

0.32% more ownership

Funds ownership: 68.76% → 69.08% (+0.32%)

0% more funds holding

Funds holding: 158 → 158 (0)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

Holders
158
Holders Change
–
Holders Change %
0%
% of All Funds
2.48%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
26
Increased
58
Reduced
43
Closed
26
Calls
$1.04M
Puts
$765K
Net Calls
+$272K
Net Calls Change
+$22K

Top Buyers

1
KA
Kinnevik AB
Sweden
+$19.3M
2
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
+$8.22M
3
AIM
ARK Investment Management
Florida
+$8.13M
4
BlackRock
BlackRock
New York
+$6.91M
5
LIM
Lingotto Investment Management
United Kingdom
+$5.42M

Top Sellers

1
LCM
Laurion Capital Management
New York
-$11.5M
2
Norges Bank
Norges Bank
Norway
-$9.51M
3
State Street
State Street
Massachusetts
-$4.72M
4
HMC
Harvard Management Company
Massachusetts
-$4.39M
5
Millennium Management
Millennium Management
New York
-$4.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
101
STRS Ohio
Ohio
$167K +$11.9K +1,700 +8%
Handelsbanken Fonder
102
Handelsbanken Fonder
Sweden
$167K +$25.2K +3,600 +19%
GWM
103
GoalFusion Wealth Management
Texas
$149K – – –
HSBC Holdings
104
HSBC Holdings
United Kingdom
$148K +$63K +9,004 +86%
CC
105
Corton Capital
Ontario, Canada
$148K -$90K -12,860 -39%
FRM
106
Fox Run Management
Connecticut
$141K +$15.3K +2,183 +13%
TRCT
107
Tower Research Capital (TRC)
New York
$138K +$25K +3,574 +24%
IC
108
IEQ Capital
California
$134K – – –
VIA
109
Vident Investment Advisory
Georgia
$133K +$12K +1,716 +11%
EFM
110
E Fund Management
China
$129K -$29.3K -4,188 -20%
GC
111
Guggenheim Capital
Illinois
$126K +$118K +16,812 New
Commonwealth Equity Services
112
Commonwealth Equity Services
Massachusetts
$117K +$109K +15,635 New
PAMS
113
Pictet Asset Management (Switzerland)
Switzerland
$112K +$105K +14,987 New
Royal Bank of Canada
114
Royal Bank of Canada
Ontario, Canada
$108K +$46K +6,581 +83%
ETC
115
Exchange Traded Concepts
Oklahoma
$107K +$100K +14,300 New
EWM
116
Empirical Wealth Management
Washington
$100K +$93.9K +13,420 New
AB
117
Amalgamated Bank
New York
$100K -$8.31K -1,188 -8%
CF
118
Centaurus Financial
California
$99K +$15.5K +2,219 +20%
Victory Capital Management
119
Victory Capital Management
Texas
$92.1K -$2.02K -288 -2%
HF
120
HRT Financial
New York
$91K -$1.09M -156,063 -93%
JF
121
Jump Financial
Illinois
$88.5K -$823K -117,692 -91%
D.E. Shaw & Co
122
D.E. Shaw & Co
New York
$88.5K -$1.34M -191,053 -94%
P
123
Pitcairn
Pennsylvania
$87.9K +$82.3K +11,763 New
AIP
124
Ameritas Investment Partners
Nebraska
$84.2K +$7.9K +1,129 +11%
VEA
125
Virtus ETF Advisers
New York
$82.4K -$399 -57 -0.5%
3 4
5
6 7

RXRX Hedge Fund Activity: Q2 2023 in Review

158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.

Fund positioning in RXRX was balanced in Q2 2023: 26 funds opened new positions, 26 closed out, 58 added to existing stakes and 43 trimmed.

The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.

  • 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 26 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of 0 holders.
  • The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
  • The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2023.